Objective: To investigate the impact of single or repeated episodes of reversible demyelination on long-term locomotor performance and neuroaxonal integrity, and to analyze the myelin proteome after remyelination and during aging. Methods: Long-term locomotor performance of previously cuprizone-treated animals was monitored using the motor skill sequence (MOSS). Quantitative analysis of myelin proteome and histopathological analysis of neuronal/axonal integrity was performed after successful remyelination. Histopathological findings observed in experimental chronic remyelinated lesions were verified in chronic remyelinated lesions from multiple sclerosis (MS) patients. Results: Following cessation of cuprizone treatment, animals showed an initial recovery of locomotor performance. However, long after remyelination was completed (approximately 6 months after the last demyelinating episode), locomotor performance again declined in remyelinated animals as compared to age-matched controls. This functional decline was accompanied by brain atrophy and callosal axonal loss. Furthermore, the number of acutely damaged amyloid precursor protein-positive (APPþ) axons was still significantly elevated in long-term remyelinated animals as compared to age-matched controls. Confocal analysis revealed that a substantial proportion of these APPþ spheroids were ensheathed by myelin, a finding that was confirmed in the chronic remyelinated lesions of MS patients. Moreover, quantitative analysis of myelin proteome revealed that remyelinated myelin displays alterations in composition that are in some aspects similar to the myelin of older animals. Interpretation: We propose that even after completed remyelination, axonal degeneration continues to progress at a low level, accumulating over time, and that once a threshold is passed axonal degeneration can become functionally apparent in the long-term. The presented model thus mimics some of the aspects of axonal degeneration in chronic progressive MS. View this article online at wileyonlinelibrary.com.
M ultiple sclerosis (MS) is the most common disabling neurological disease in young adults (reviewed in Friese and colleagues, 1 Trapp and colleagues, 2 and Noseworthy and colleagues 3 ). Disability often becomes apparent as a result of repeated attacks, followed by partial or complete remission of neurological symptoms (relapsing-remitting MS [RRMS] ), which in turn is followed by a phase of gradually worsening clinical symptoms (secondary progressive MS [SPMS] ). Moreover, some MS patients show a steady neurological decline even in the absence of acute attacks (primary progressive MS [PPMS] ).
Supported by histopathological and magnetic resonance imaging (MRI) studies, 4 ,5 it appears clear that axonal loss is a key determinant of permanent disability in patients with MS. Acute axonal damage is most extensive in the early stages of the disease, 6 and the highest degree of acute axonal damage is associated with active demyelination. [7] [8] [9] In addition to resolution of inflammation, remyelination can restore axonal conduction properties and is thought to contribute to the improvement of neurological function during remission in RRMS. 10, 11 However, since the disability is permanent and irreversible in the progressive phase, it is important to elucidate what determines the transition into this stage. The accumulation of noncompensable axonal loss mediated by inflammatory processes may explain the development into a progressive form of the disease. Indeed, inflammatory infiltrates were invariably associated with axonal damage, not only in RRMS but also in chronic progressive MS. 12 However, it is still poorly understood why current immunomodulatory treatment reduces the relapse rate but does not prevent the increasingly permanent neurological deficits in progressive MS. One explanation might be that inflammatory cells are trapped behind an intact blood-brain barrier in progressive MS and are thus no longer accessible to the therapeutic treatment. A further explanation may, however, be that ongoing degeneration does not solely rely on inflammation. 13, 14 Age is an important risk factor for MS progression. 10, 11 Studies have shown that the progressive phase is an age-dependent process, starting at a mean age of 39 years. 15 Regardless of the disease subtype-primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), or 1 relapse followed by progression-the average age at which patients enter the progressive stage is strikingly similar. 15 In addition, once a clinical threshold of disability is reached, the number of relapses is not prognostic for the further clinical course. 16 This raises the possibility that age-related processes are relevant for the initiation of the progressive phase of the disease.
Here we studied the long-term functional impact of demyelination in the C57BL6 cuprizone mouse model of MS. [17] [18] [19] We provide evidence that after a phase of initial functional recovery, locomotor decline occurred long after completed remyelination. This suggests that mechanisms operating indepently of acute inflammation may also contribute to the long-term disability and may be of importance for our understanding of disease progression in MS.
Subjects and Methods

Mice and Cuprizone Treatment
Eight-week-old C57Bl6 mice were assigned to 3 groups, namely double demyelination (DD), single demyelination (SD), and control (see also Fig 1) . DD animals were fed with 0.25% cuprizone (Sigma, St. Louis, MO) in milled chow for 5 weeks, followed by a normal diet for 4 weeks. Subsequently, they received a 0.25% cuprizone diet for 5 weeks, which was then replaced by a normal diet for the rest of the experiment. Animals in the SD group received a normal diet for 9 weeks (until the start of the second demyelinating event of group DD), were then fed with 0.25% cuprizone for 5 weeks, and finally were fed with a normal diet for the rest of the experiment. Age-matched controls received a normal diet throughout the experiment.
FIGURE 1: Experimental design of cuprizone treatment. Eight-week-old mice were fed cuprizone for 5 weeks, were then allowed to recover for 4 weeks, and finally received cuprizone for 5 more weeks (DD). A second group of mice (SD) were fed cuprizone for 5 weeks simultaneous to the second demyelination of the DD group as indicated. Animals were switched to a normal diet for 28 weeks until the end of the experiment. Age-matched controls were fed with a normal diet throughout the experiment. MOSS analysis was performed at the times indicated. Animals were first habituated to training wheels composed of regularly spaced crossbars for 2 weeks. Subsequently, running performance on complex wheels was recorded for an additional week. DD 5 double demyelination; MOSS 5 motor skill sequence; SD 5 single demyelination.
Motor Skill Sequence
Assessment of motor performance following remyelination was carried out as previously described using the motor skill sequence (MOSS). 20 Separate analyses were performed 6, 20, and 28 weeks after cuprizone removal from the diet (see Fig 1) . For every MOSS session, each animal was transferred to an individual cage and was allowed to run voluntarily on a training wheel with regularly spaced crossbars for 14 days. Subsequently, the wheel was replaced by a ''complex'' wheel containing irregularly-spaced crossbars and the animals were allowed to run voluntarily for 7 consecutive days. The following parameters were monitored continuously: maximum running velocity in revolutions/min (V max ), accumulated distance in meters (Dist ac ), number of individual runs (N run ), accumulated running time (T total ), and maximum distance per run (Dist max ). Dist ac , T total , and N run represent the values accumulated during the last 24 hours, whereas V max and Dist max represent the maximum values achieved during that time.
Human Brain Tissue
Human brain autopsies of MS patients were obtained from the Department of Neuropathology collection at the University Medical Center Göttingen. Their use for scientific purposes was approved by the ethics committee of the University of Göttin-gen (Göttingen, Germany).
Histology
Animals were sedated with a 14% chloral hydrate intraperitoneal injection, perfused transcardially, brain were fixed with 4% paraformaldehyde (PFA). Tissue was processed and embedded in paraffin as described 21, 22 to obtain 1lm-thick coronal and sagittal sections. Luxol fast blue-periodic acid Schiff (LFB-PAS) staining was performed to assess the extent of demyelination according to a standardized score ranging from 0 (no demyelination) to 3 (complete demyelination). 23 Immunohistochemistry was performed using antibodies against activated microglia/macrophages (Mac3 clone M3/84; BD Bioscience, NY, USA), astrocytes (glial fibrillary acidic protein [GFAP] clone 6F2; Dako, Hamburg, Germany), neuronal nuclei (NeuN; Chemicon, Temecula, CA), axonal damage with amyloid precursor protein (APP, clone 22C11; Chemicon), and myelin basic protein (MBP, A0623; Dako), followed by labeling with biotinylated secondary antibodies. Avidin-biotin technique with 3,3-diaminobenzidine was used for visualization. Fluorescent immunohistochemistry was performed for APP, MBP, and neurofilament 200 (NF200, clone N52; Sigma) with Cy2-conjugated donkey anti-mouse immunoglobulin G (IgG) and Cy3-conjugated goat anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch Laboratories, Suffolk, UK). Histological sections stained with anti-APP, Mac3, NeuN, and GFAP antibody, and counterstained with haemalum were scanned using the Dotslide System (Olympus GmbH, Hamburg, Germany), coupled to an Olympus BX51 microscope.
For axonal counting on sagittally cut sections paraffinembedded sections were stained against neurofilament (1:600; monoclonal mouse anti-human neurofilament protein, clone 2F11, Dako M0762; Dako) and detected with a secondary fluorescent-labeled antibody (1:200; Alexa FluorV R 555 goat antimouse IgG1, Invitrogen A21127; Invitrogen, NY, USA). Tissue was counterstained with DAPI nucleic acid stain (1:10,000; D3571; Invitrogen) and sections were coverslipped with Fluoprep (bioM erieux).
Axonal densities of corpus callosum were assessed by 2 independent methods:
1. Densitometric measurements of callosal axons were performed on coronal NF200-stained sections. Images were obtained at each side of the midsagittal line of the corpus callosum under equal acquisition parameters with a confocal microscope (LSM 510; Carl Zeiss MicroImaging, Inc., Göttingen, Germany or TCS SP2 AOBS; Leica, Solms, Germany) and the signal intensity was analyzed with Image J. To examine whether APPþ axons were myelinated, fluorescence immunohistochemistry of sagittal sections of the corpus callosum was performed with APP and MBP antibodies, and the presence of an MBP-positive signal surrounding APP was determined.
2. Callosal axons were evaluated on sagittal neurofilamentstained brain sections. Images of transversally cut axons were obtained by a Zeiss LSM 510 laser scanning microscope coupled to a Zeiss Axiovert 100 M inverted microscope equipped with a Â63/1.4 oil immersion objective. Callosal axons were captured in 3 to 5 randomly selected, non-overlapping areas (146.2 Â 146.2lm 2 ) per animal. Confocal stacks (thickness of 1.2-3.7lm; interval of 0.41lm) were scanned in the z-direction (Software LSM 510; Zeiss) and 3 to 5 overlapping stacks composed 1 layer using Fiji. We counted axons in an area of at least 5,600lm 2 per animal using a custom-programmed script in Cognition Network Language-based on the Definiens Cognition Network Technology platform (Definiens Developer XD software; Definiens AG, Munich, Germany). The Cognition Network Language is an object-based procedural computer language which is specifically designed for automated analysis of complex, context-dependent image analysis tasks. 24 In brief, neurofilament-positive axons were detected based on their contrast to the image background signal. To adapt for potential variable background staining levels, the area surrounding potential axonal structures was segmented and the mean intensity difference between the structures was calculated. Neurofilament-positive structures displaying a signal difference higher than 8 from their surroundings were classified as axons (for detailed formula see the Definiens Developer XD 1.5.2 Reference book). Complementary, adjacent sections were stained using Bielschowsky's silver impregnation technique and sections were scanned using Zeiss Mirax Virtual Slide Scanner (Carl Zeiss MicroImaging GmbH). The thickness of the corpus callosum was then measured using a Mirax Slide Viewer (Carl Zeiss MicroImaging GmbH). Axonal numbers were subsequently calculated by multiplying axonal densities (expressed as axons per square millimeter) with the thickness of the corpus callosum of a given animal.
Human Tissue Staining
Histopathological analysis was performed on PFA-fixed sections from brain autopsies of patients with documented progressive MS. All tissue blocks (n ¼ 6 blocks from 4 patients) were selected if signs of remyelination (judged by LFB/PAS staining) were observed. Fluorescence immunohistochemistry was performed for MBP and APP.
Analysis of Neuronal Numbers
Sections stained for neuronal nuclei with NeuN antibodies were scanned. Neuronal numbers were automatically counted using a script in Cognition Network Language based on the Definiens Cognition Network Technology platform. Briefly, the cortical region of interest was drawn manually and NeuN-positive cells were detected based on color criteria. After finer segmentation to discriminate between nucleus and cytoplasm, the object was classified as a NeuN-positive cell if the soma was below a certain size and had 0 to 1 nuclei. If more than 1 nucleus was detected within 1 soma, the object was split using each nucleus as seed to grow into the surrounding cytoplasm, stopping if growing borders converged or the cytoplasmic border was reached. Finally, the total number and density of NeuN-positive cells was calculated. 
Statistical Analysis
Electron Microscopy
Electron microscopy was performed according to a modified protocol as described. 21 Briefly, mice were fixed by transcardial perfusion with 4% PFA and 2.5% glutaraldehyde in 0.1M phosphate buffer containing 0.5% NaCl. The tissue was embedded in Epon, the corpus callosum was cut and stained with toluidine blue, and ultrathin sections were cut and treated with uranyl acetate and lead citrate. The sample area was selected at low magnification in the electron microscope (Â2,500) before systematically recording images at Â16,000 magnification using a CCD camera (MegaView III, Soft Imaging System). Axon diameters and myelin sheath thicknesses of at least 300 axons (>0.35lm in diameter) were measured from each animal using CellF software (Olympus Soft Imaging Solutions GmbH, Germany), to calculate the g-ratio (axon diameter/fiber diameter) as described. 25 
Proteomic Analysis of Myelin
Animal experiments were conducted in accordance with animal protection laws approved by the Government of Lower Saxony, Germany. Three young (12 weeks old) and 3 old (over 20 months old) C57BL/6J mice were sacrificed by cervical dislocation and their complete brains were extracted and frozen. In addition, 8-week-old C57BL/6J mice were fed for 6 weeks with 0.2% cuprizone mixed in normal chow, followed by 6 weeks of normal diet. Samples of the corpus callosum of the cuprizonefed and age-matched control mice were obtained and frozen.
Myelin Isolation and Purification
Myelin was isolated according to a modified protocol as previously described 26 to obtain purified myelin. All steps were performed on ice in a SW41 Ti rotor with an Optima XL-70 ultracentrifuge (Beckman Coulter, Krefeld, Germany) and the protein concentration of the myelin preparation was measured with the Bradford method. 27 
Sample Preparation, Isobaric Tags for Relative and Absolute Quantitation Labeling and Strong Cation Exchange Fractionation
Equal amounts of purified myelin (15lg for young and old samples, and 8lg for remyelinated and control samples) were resuspended in 0.85% RapiGest in 50mM triethylammonium bicarbonate (TEAB), treated with reducing agent (isobaric tags for relative and absolute quantitation [iTRAQ] Reagents Multiplex Kit, Applied Biosystems, Carlsbad, USA) and alkylated with iodoacetamide. After trypsin digestion, peptides labeled with iTRAQ reagents were pooled together in pairs (young vs old and remyelinated vs control). Each pooled sample was separated by strong cation exchange (SCX) fractionation (ICAT Cartridge Kit; Applied Biosystems), eluted stepwise by 300ll injection of KCl solutions (5-1,000mM, 25% acetonitrile, and pH 2.7-3.0). Further purification and desalting was performed on a reverse-phase microcolumn, as described. 28 
Mass Spectrometry and Analysis
Purified myelin samples from young and old mice as well as remyelinated animals and their age-matched controls were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Each purified sample was injected onto a C18 reverse-phase column (Reprosil; Maisch, Germany) and eluted at 200nl/min with different mobile phase B concentrations (7-40%) in an 80% acetonitrile and 0.15% formic acid solution. Mass spectrometry analysis of the digested peptides was carried out using a Thermo LTQ XL Orbitrap (Thermo Fisher Scientific, Bremen, Germany) coupled to an Agilent 1100 series LC system. Peak lists were searched against the National Center for Biotechnology Information (NCBI) nonredundant reference sequence (RefSeq) database (http:// www.ncbi.nlm.nih.gov/RefSeq) 29 using Mascot v.2.2 as a search engine (Matrix Science, Boston, MA). 30 Mass accuracy was 5ppm for both parent ion and fragment ions. The peptides were constrained to be tryptic with a maximum of 2 missed cleavages. Only proteins with a Mascot score over 25 were ANNALS of Neurology considered in the data set. To correct for a bias due to unequal protein mixing, the data set was normalized by dividing the raw peptide ratios with their median value, which resulted in a balanced distribution at a ratio of approximately 1:1. Proteins identified from peptides with a ratio >1.2 or <0.8 can be considered differentially expressed, as described. [31] [32] [33] [34] The possible localization and function of proteins was determined using the UniProt Knowledgebase (UniProtKB) protein database (http:// www.uniprot.org/help/uniprotkb). 35 Transmembrane proteins were predicted using the TMHMM2.0 (Krogh and colleagues 36 ) or Phobius software. 37 
Results
We examined the long-term impact of cuprizone-induced demyelination and remyelination using the following paradigm (see scheme of Fig 1 for experimental design) : a first group of mice was subjected to DD by feeding 8-week-old mice with cuprizone for 5 weeks and allowing them to recover for 4 weeks before cuprizone treatment was repeated for 5 more weeks. A second group of mice (SD) were fed once with cuprizone for 5 weeks, simultaneously with DD group's second exposure to cuprizone. Thereafter, animals of both DD and SD groups were fed normal diets for 28 weeks. Age-matched controls were fed a normal diet throughout the experiment. Locomotor performance was assessed using MOSS analysis within a time span of $6 months at 3 different time points following discontinuation of cuprizone (see Fig 1) . MOSS is an automated complex wheel test particularly suited to detect latent motor deficits after cuprizone-induced demyelination. 20, 38 Six weeks after cuprizone removal, both treated groups (SD and DD) exhibited similar locomotor performance in parameters reflecting general motivation and fitness (N run , T total , and Dist ac ; Fig 2, left panel) compared to age-matched controls. However, V max and D max were still significantly reduced in both groups compared to age-matched controls. Previous studies suggested that reduced maximal running performances were related to impaired capacity of complex bihemispherical motor coordination. 39 Furthermore, these findings were congruent with earlier findings showing that motor deficits are still evident after 6 weeks of recovery following a cuprizone diet. 20, 38 We re-examined the animals 14 weeks later (ie, 20 weeks of recovery), and in contrast to the first MOSS measurement, locomotor performance of remyelinated animals was indistinguishable from age-matched controls. These results indicate that remyelination, probably in combination with neuroplastic processes, can restore locomotor function in the medium-term following demyelination. To further investigate whether functional recovery remained stable in the long term, we repeated MOSS analysis 28 weeks after stopping cuprizone. At this final time point, remyelinated animals (irrespective of single or repeated prior exposure to cuprizone) displayed deteriorated locomotor performance as compared to agematched controls in V max and D max (see Fig 2, right  panel) . In contrast, no differences were detected in wheel-running parameters assessing motivation and/or fitness in animals previously treated with cuprizone compared to controls. Similarly, no differences in any of the locomotor parameters measured by MOSS were observed between single and double cuprizone-treated groups. These data showed that mice can completely recover following cuprizone treatment, but redevelop late-onset functional deficits. In parallel, we performed histomorphologic analysis in a subset of animals that were treated in the same manner as the mice used for MOSS measurements. Callosal demyelination was first evaluated according to a standardized score from 0 (no demyelination) to 3 (complete demyelination) on LFB/PAS-stained coronal sections. 23 Consistent demyelination of the corpus callosum following 5 weeks of cuprizone feeding was observed (see Fig 3) . LFB/PAS analysis furthermore indicated that demyelination was, to a large extent, reversible in animals subsequently exposed for 28 weeks to a normal diet (see Fig 3B) . To assess remyelination on an individual axonal level, we performed electron microscopic examination, which is the gold standard for the evaluation of remyelination. 40 We determined the fraction of nonmyelinated fibers in percentage of total fibers and calculated the g-ratio (axon diameter/fiber diameter) (Fig 4A-C) . Oneway ANOVA indicated significant differences between the experimental groups tested with regard to the g-ratio (p < 0.01) and percentage of unmyelinated fibers (p < 0.05). Post hoc analysis further revealed statistically significant differences in the g-ratio when comparing the control group to the remyelinating groups at 6 weeks or the DD group at 28 weeks, respectively (6 weeks: 0.80 6 0.008, DD: 0.8 6 0.012, control: 0.73 6 0.010). In contrast, no significant difference of the g-ratio was noted when comparing the different remyelinating groups. Similarly, the percentage of unmyelinated fibers was significantly (p < 0.05) elevated in the DD group (26 6 8.8%) and the 6-week group (23 6 2.6%) as compared to the control group (5.9 6 1.2%). No significant difference was found in the percentage of unmyelinated fibers when comparing the different remyelinated groups to each other (6 weeks, 28-week SD, and 28-week DD). Furthermore, a trend, but not a statistically significant difference, was observed when comparing the SD group to the control group with regard to percentage of unmyelinated fibers (20 6 8.4%, p ¼ 0.068) and the g-ratio (0.77 6 0.018, p ¼ 0.12) due to the slightly higher variability of recorded values in the DD group.
We also evaluated axonal densities and axonal numbers in the corpus callosum using 2 independent methods. First, axons were immunohistochemically visualized FIGURE 2: Late-onset latent motor deficits as measured by wheel-running performance after remyelination. Animals received 1 (red) and 2 (green) cycles of cuprizone to induce demyelination and were allowed to recover for 28 weeks, during which MOSS performance was compared to age-and sex-matched controls (black). Recording was preceded by a 2-week training session (day 21: performance of last day on training wheels, for details see Subjects and Methods). Complex wheel performance (days 1 to 7) is shown as follows: 6 weeks (left panels), 20 weeks (central panels), and 28 weeks (right panels) after cuprizone withdrawal. Differences between the cuprizone and control group with regard to wheel-running performance were calculated by repeated measurements ANOVA. If ANOVA indicated significant differences in the main effect (p < 0.05), Fisher's LSD post hoc tests were applied. *p < 0.05, **p < 0.01, rpm: revolutions per minute (n 5 8-12 animals per group). ANOVA 5 analysis of variance; DD 5 double demyelination; Dist ac 5 distance in meters accumulated in 24 hours; Dist max 5 maximum distance per run; LSD 5 lest significant difference; MOSS 5 motor skill sequence; N run 5 number of individual runs in 24 hours; SD 5 single demyelination; T total 5 accumulated running time in 24 hours; V max 5 maximum running velocity in revolutions per minute in 24 hours.
on coronal sections and relative axonal densities were determined by densitometry (Fig 5A-D) . This analysis revealed a substantial axonal loss in animals that remyelinated for 28 weeks as compared to untreated controls (see Fig 5D) . Second, we quantified the numbers of crossing fibers on sagittally cut sections during advanced remyelination (3 weeks of remyelination) and after terminated remyelination 6 weeks and 28 weeks after stopping cuprizone. In doing so, we found a significant drop in axonal numbers in the corpus callosum during ongoing remyelination (3 weeks vs 6 weeks after stopping cuprizone) and following completed remyelination (6 weeks vs 28 weeks of remyelination). Together, these results show that a low degree of axonal degeneration continued even after remyelination had been accomplished. In parallel to these analyses, we noted a moderate but significant increase in activated microglia and astrocyte density in remyelinated animals as compared to age-matched controls at the final time point (Supplementary Fig S1) .
To further evaluate ongoing axonal damage in the late stages, we determined APP levels in the axons at 28 weeks after cuprizone removal. Previous studies have shown that axonal accumulation of APP represents a reliable measure of acute axonal injury. Time-lapse imaging has revealed that APP accumulates locally in a damaged axon, where it can either disappear because the axon degenerates or disappear because axonal transport is restored. 24 Strikingly, APP-positive axons were still detectable in the corpus callosum of mice that were fed with cuprizone 6 months before, but virtually absent in control animals (Fig 6A,B) . Together, these data strongly support our conclusion that axonal damage, and probably also degeneration, continue long after the demyelinating trigger has been removed. To determine the proportion of unmyelinated vs myelinated axons showing axonal dysfunction, sagittal sections of the corpus callosum were double-stained for APP and MBP. Interestingly, a significant fraction (19% for DD and 27% for SD) of APP-positive axons was ensheathed by MBP-positive myelin (see Fig 6C,D) . To verify whether this also occurs in MS, we performed similar staining on autopsy lesions showing extensive remyelination and with a documented long clinical history of progressive MS (n ¼ 6 lesions of 4 MS cases, average disease duration 17.2 6 4.7 years). Similarly, we found APP-positive axons in remyelinated lesions, and the fraction of myelin-ensheathed, APP-positive axons was 14%, thus confirming our results obtained in remyelinated animals following cuprizone treatment (see Fig 6E,F) .
Several studies have highlighted the importance of brain atrophy in permanent neurological impairment. [41] [42] [43] [44] We evaluated the cortical thickness of coronal sections 28 weeks after stopping cuprizone (week 42; see Fig 1) in 3 different regions: medial, paramedial, and lateral (Fig 7D) . Whereas the medial and lateral regions showed no differences in cortical thickness (ANOVA, p > 0.05), a significant decrease was detected in the paramedial region (ANOVA, p < 0.01) (see Fig 7E-G) . In addition, we observed a marked reduction of corpus callosum thickness in the medial region. To determine whether cortical neuronal loss occurred, we performed an automated analysis of total neuronal numbers in a defined cortical area at week 42 in comparison to age-matched controls. For this purpose, neuronal nuclei in coronal sections were stained with NeuN antibodies, scanned, and NeuN-positive cells were counted automatically (for details see Subjects and Methods). However, no differences in total neuronal numbers or density were found between any of the groups (see Fig 7B) . Together, our results indicate that the insult preferentially affected axonal processes but did not cause substantial loss of neuronal somas in the cerebral cortex. Changes in myelin composition can induce axonal pathology. [45] [46] [47] Therefore, proteome analysis was designed as an exploratory approach to unravel tangible quantitative differences in myelin protein composition following remyelination compared to controls. In addition, we analyzed how myelin changes its composition in older animals (20 months old). Myelin was prepared from $12-week-old and $20-month-old mice, from mice after 6 weeks of cuprizone feeding followed by 6 weeks of recovery, and from age-matched controls. Relative quantification of the proteome was performed using iTRAQ technology coupled with MS/MS. A total of 240 proteins were detected in $12-week-old and $20-month-old mouse myelin and 349 proteins in remyelinated and age-matched control myelin. The principal myelin-associated proteins, MBP, proteolipid protein (PLP), and 2 0 ,3 0 -cyclic-nucleotide 3 0 -phosphodiesterase (CNPase), were identified with the highest protein score, as expected (see Table 1 and Supplementary  Tables S1-S3 ). Mass spectrometry analyses normally result in an overrepresentation of cytosolic proteins because membrane proteins are difficult to detect. We detected a relatively large fraction of membrane-associated proteins (30-32%), including transmembrane (21-24%) and lipid-anchored proteins (7-8%). As expected, the relative abundance of the majority of proteins appeared unaltered after completed remyelination (79% and 87% of proteins presented iTRAQ ratios between 0.8 and 1.2 in aging and remyelination analysis, respectively). The proteins with the largest relative abundance changes are presented in Tables 1 and 2 . Interestingly, regression analysis revealed a strong correlation in quantitative changes occurring during aging compared to those observed after remyelination of membrane and membrane-associated proteins (Fig 8) , even when including lipid-anchored proteins (r ¼ 0.77 for transmembrane proteins and r ¼ 0.63 when lipid-anchored proteins and MBP are included, p < 0.001 in both cases). Conversely, changes in proteins considered as contamination from myelin purification, such as cytoskeleton/cytoplasm and mitochondrial proteins, presented no correlation (r ¼ 0.04 and 0.26, respectively, and p > 0.5 in both cases). These data suggest that despite an overall stability in myelin protein composition and relative abundance, subtle changes are evident during aging and remyelination and that these changes seem to have the same tendency for both conditions. In summary, our findings indicate that late-onset locomotor dysfunction can be observed long after cuprizone-induced demyelination and remyelination. This is accompanied by a reduction of callosal axons and a low level of continuing axonal injury. Furthermore, the restoration of myelin showed changes in the myelin proteome in a pattern similar to that of older animals.
Discussion
We studied the long-term effects of cuprizone-induced demyelination. Motor skills were repeatedly evaluated after remyelination over a period of $6 months using MOSS. 20 After single or repeated demyelination, animals displayed interim functional recovery with locomotor capacity comparable to controls. However, cuprizonetreated animals displayed late-onset motor impairments, indicating that functional recovery was merely transient and not stable in the long term. Along with these functional deficits, we observed axonal loss despite extensive remyelination.
While axonal damage appears to be critical for clinical disability in chronic progressive MS, the underlying mechanisms are not resolved. Interestingly, neurodegeneration seems to primarily affect neuronal processes, because axonal loss is more frequent than loss of neuronal cell bodies. 48 In this study, cuprizone-induced demyelination caused substantial axonal loss in the corpus callosum without a significant reduction in the numbers of cortical neurons. However, although we could not discover a significant reduction of NeuN-positive neurons in the cortex with this global analysis, it is possible that in a specific neuronal subpopulation, ie, a population not detectable with our approach, the number of NeuNpositive cortical neurons might decrease. With regard to MS, it was shown that specific subpopulations of neurons are more vulnerable to demyelination. 49 We and others found that acute axonal damage is most prominent during cuprizone feeding when demyelination is most extensive. [50] [51] [52] Similarly, most APP-positive axons in MS lesions are detected within the first year after disease onset. 6, 7 In our model-and probably mechanistically distinct from axonal damage during acute demyelination-ongoing axonal degeneration was evident in remyelinated animals several months after cuprizone was removed from the diet. In addition, APP-positive spheroids were also observed in MS lesions of patients with a disease duration of 10 years and more. 2, 6 These findings raise the question of what underlying factors are contributing to axonal damage and functional impairments in the chronic disease stage long after the demyelinating trigger. Extensive spontaneous repopulation of oligodendrocytes and remyelination is achieved within a few weeks after discontinuation of cuprizone, and axonal damage seems to localize in regions of demyelination and remyelination. Nevertheless, cuprizone could exert longlasting toxic effects that selectively affect axons in the long term and that may only become apparent at chronic time points. Therefore, we cannot formally rule out the contribution of long-lasting cuprizone effects to axonal degeneration. Similarly, in the current study we cannot exclude the possibility that remyelination was temporarily more complete at the intermediate time point (20 weeks) , when full functional recovery was noted. However, previous studies found that after cuprizone was discontinued, a maximal degree of remyelination was achieved within a few weeks and did not substantially change over an observation period of several months. 22, 53, 54 A recent study found a close association between axonal degeneration and inflammation even in MS patients with a long disease duration, albeit at a lower level than in acute/RRMS. 12 We also observed a moderate increase of microglia density in remyelinated lesions ANNALS of Neurology in the animal model and in the MS lesions studied (see Supplementary Fig S1 , and data not shown). However, it is still not clear whether this low level of inflammation is the cause or the consequence of ongoing axonal degeneration at these chronic stages. In addition, immunomodulatory therapies have shown little effect in preventing permanent neurological deficits in progressive MS. Thus, in progressive disease stages, inflammation might not be the sole driving force in axonal degeneration. How such slowly accumulating axonal pathology could contribute to a transition from RRMS to SPMS is still not understood. Early functional recovery from irreversible axonal damage might be achieved by adaptive neuroplasticity mechanisms. 55 However, if axonal degeneration continues at a low level-even in the absence of newly emerging demyelinating insults and/or even after extensive remyelination-the degree of axonal loss could reach a critical threshold at which neuroplastic responses are exhausted and thus progressive clinical symptoms may reappear. 4, 56 We propose that even after completed remyelination, axonal degeneration still continues at a low level and accumulates over time, and that once a threshold is passed, axonal degeneration becomes functionally apparent in the long-term. Strikingly, 2 episodes of cuprizoneinduced demyelination did not increase or accelerate lateonset functional deterioration compared to a single episode. This might be due to increased resistance to repeated episodes of cuprizone-induced demyelination, 57 but it might also have to do with the age at which animals were last exposed to cuprizone: the SD group received its first and only cuprizone treatment at the same age as the DD group was when it was exposed to cuprizone for the second time (see Fig 1) . It was previously reported that axonal damage and loss is more severe when animals are subjected to cuprizone treatment at an older age. 50 Thus, it is possible that, for the functional outcome, the age at the time of the last cuprizone treatment is decisive. At the time of its only cuprizone exposure, the SD group may already have been catching up with the DD group. Interestingly, in MS the number of relapses do not correlate with the severity and time of onset of chronic progressive MS. 58 In fact, age is the most important risk factor for chronic progressive MS. 58 It has been shown that myelin provides the trophic support for axons necessary for their maintenance into late adulthood, 59 and its stability depends on constant remodeling and turnover. However, myelin renewal is not necessarily linked to the preservation of its integrity, as several ultrastructural defects accumulate in the myelin sheath during aging. 60 Some authors even claim that disruption of myelin integrity is related to the cognitive decline observed in aging. [61] [62] [63] It has been proposed that the decrease in axonal conduction velocity observed in aging brains 64 and in regions where myelin has been altered 65 affects the transmission of electric signals along the axon, which may disturb normal function in neural circuits necessary for complex behavior and fast response. 60 Ultrastructural changes such as shorter internodes reported during aging suggest an active process of remyelination in the absence of any apparent demyelinating event. 66 In addition, myelin is essential for long-term axonal survival and minor alterations in myelin membrane composition can trigger neurodegeneration. [45] [46] [47] 59 It has been reported that the myelin sheath formed after remyelination seems to be ultrastructurally and chemically normal, although it is thinner. 67 In accordance with these findings, we observed that the relative abundance of myelin proteins is unchanged after 6 weeks of remyelination. However, we also found that the subtle changes in the proteome of myelin after remyelination were similar to those of myelin in aged animals. For instance, we observed an increase in relative amount of membrane spanning protein claudin 11 (see Table 1 and 2) following remyelination. This protein is involved in the formation and stabilization of the radial component. The radial component is thought to modulate the biophysical properties of myelin by providing a diffusion barrier for ions within myelin. 68 Changes in the expression of tight junctions within the radial component may lead to small temporal alteration in nerve transmission. It is also possible that an increased expression of claudin 11, which spans 4 membranes, results in oligodendroglial damage, as was observed in Pelizaeus-Merzbacher disease after overexpression of PLP. 69 Furthermore, claudin 11 is known to be involved in the formation of tight junctions in the radial component of myelin sheaths, as well as in oligodendrocyte proliferation and development. 70 Mice lacking claudin 11 present a slower electric conduction of the axons and their myelin does not contain tight junctions, possibly resulting in diminished insulating properties; absence of claudin 11 results in neurological deficits despite normal compaction. 71 The present results may provide a source of candidate proteins involved in myelin functional maintenance for use in future studies. However, our analysis does not exclude the possibility that other properties of myelin not detected in our analysis (eg, alteration in posttranslational modification) may account for the observed axonal degeneration in the long term. It is possible that changes in myelin occurring after episodes of demyelination and remyelination are sufficient to induce late-onset neuronal dysfunction which only becomes apparent when mice reach an advanced age. Concomitant with this assumption is our finding that some of the APP-positive axons were ensheathed in myelin 6 months after stopping cuprizone. If changes in myelin content result in impaired axonal trophic support in the long term, inflammatory cells could be recruited secondary to the site of axonal degeneration.
It should be mentioned that numerous studies provide evidence that remyelination is advantageous for axonal function. Replacement of damaged myelin not only restores nerve conduction 72 but also provides a neuroprotective function by reducing axonal degeneration. 51 The beneficial function of myelin has been shown in numerous studies and is undisputed. 11, 51, [73] [74] [75] However, the current data indicate that minor alterations accumulating in remyelinated myelin can result in subtle changes in axonal function that may only become functionally relevant in the long term. Whether any of these important functions are lost in older animals after inducing episodes of demyelination and remyelination is an important question that must be addressed in future studies. In summary, cuprizone-induced demyelination results in temporary functional recovery but at a later time point leads to late-onset motor impairment. Novel therapeutic approaches for neuroprotection not only need to reduce acute but also long-term axonal damage. The model presented here mimics some of the aspects of axonal pathology observed in chronic progressive MS and might therefore be useful, not only to study the factors triggering and maintaining long-lasting axonal damage, but also to evaluate neuroprotective treatment strategies.
